{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["69964ea4-cf0a-4f22-ae35-6dc3d7f02f90", "Q1", 400703107, "THE GIBSON GROUP, LLC", 194417, "ASSOCIATION FOR ACCESSIBLE MEDICINES", 2026, "first_quarter", "2026-04-09T14:10:03-04:00", 60000.0, 0, 0, 0, "{\"url\": \"https://lda.gov/api/v1/filings/69964ea4-cf0a-4f22-ae35-6dc3d7f02f90/\", \"filing_uuid\": \"69964ea4-cf0a-4f22-ae35-6dc3d7f02f90\", \"filing_type\": \"Q1\", \"filing_type_display\": \"1st Quarter - Report\", \"filing_year\": 2026, \"filing_period\": \"first_quarter\", \"filing_period_display\": \"1st Quarter (Jan 1 - Mar 31)\", \"filing_document_url\": \"https://lda.gov/filings/public/filing/69964ea4-cf0a-4f22-ae35-6dc3d7f02f90/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"60000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Joseph H. Gibson\", \"dt_posted\": \"2026-04-09T14:10:03-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"601 Thirteenth Street, N.W.\", \"registrant_address_2\": \"Suite B2 North\", \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20005\", \"registrant\": {\"id\": 400703107, \"url\": \"https://lda.gov/api/v1/registrants/400703107/\", \"house_registrant_id\": 41536, \"name\": \"THE GIBSON GROUP, LLC\", \"description\": \"â\\u20ac\\u2039Government Affairs Consulting Firm.\", \"address_1\": \"601 Thirteenth Street, N.W.\", \"address_2\": \"Suite B2 North\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20005\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"JOSEPH GIBSON\", \"contact_telephone\": \"+1 202-744-2827\", \"dt_updated\": \"2026-02-26T10:08:05.696799-05:00\"}, \"client\": {\"id\": 194417, \"url\": \"https://lda.gov/api/v1/clients/194417/\", \"client_id\": 140, \"name\": \"ASSOCIATION FOR ACCESSIBLE MEDICINES\", \"general_description\": \"National trade organization representing the interests of generic drug manufacturers.\", \"client_government_entity\": false, \"client_self_select\": null, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"DC\", \"ppb_state_display\": \"District of Columbia\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2016-09-01\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"Drug competition issues Monitor drug supply chain issues\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54211, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOSEPH\", \"nickname\": null, \"middle_name\": \"H\", \"last_name\": \"GIBSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997\", \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"LBR\", \"general_issue_code_display\": \"Labor Issues/Antitrust/Workplace\", \"description\": \"Drug competition issues\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54211, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOSEPH\", \"nickname\": null, \"middle_name\": \"H\", \"last_name\": \"GIBSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997\", \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"CPT\", \"general_issue_code_display\": \"Copyright/Patent/Trademark\", \"description\": \"Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Monitor S. 1040 - product hopping Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54211, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOSEPH\", \"nickname\": null, \"middle_name\": \"H\", \"last_name\": \"GIBSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997\", \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"TRD\", \"general_issue_code_display\": \"Trade (domestic/foreign)\", \"description\": \"Monitor issues related to trade agreeements\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54211, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOSEPH\", \"nickname\": null, \"middle_name\": \"H\", \"last_name\": \"GIBSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997\", \"new\": false}], \"government_entities\": []}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}", "DC", "US", 41536, "DC", "DC", "US", "US", "National trade organization representing the interests of generic drug manufacturers.", 0, 0, 987797, null, "normalized_name_state", 0.9]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json", "registrant_state", "registrant_country", "registrant_house_id", "client_state", "client_ppb_state", "client_country", "client_ppb_country", "client_general_description", "client_government_entity", "affiliated_org_count", "client_entity_id", "client_government_unit_id", "client_match_method", "client_match_confidence"], "primary_keys": ["filing_uuid"], "primary_key_values": ["69964ea4-cf0a-4f22-ae35-6dc3d7f02f90"], "units": {}, "query_ms": 17.164468998089433, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}